ArticleBiological psychiatry2020
Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder.
Article in Biological psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 57 citations in OpenAlex.
- Low-dose naltrexone as an adjunctive treatment for major depressive disorder: findings from a randomized, double-blind, placebo-controlled hybrid parallel-arm study.Frontiers in pharmacology · 2026Trial
- Trial
- Neurobehavioral Effects of Two Distinct Anti-Inflammatory Drugs in a Two-Week Chronic Stress Model in Zebrafish.Brain sciences · 2026Article
- Neuroprotective and Antidepressant Effects ofExperimental neurobiology · 2026Article
- Neuroinflammatory Mechanisms in Depression: From Biomarkers to Anti-Inflammatory Therapy.Brain sciences · 2026Review
- PET Imaging Unveils Neuroinflammatory Mechanisms in Psychiatric Disorders: From Microglial Activation to Therapeutic Innovation.Molecular neurobiology · 2025Review
- Imaging brain inflammation and blood brain barrier permeability in neurological and psychiatric diseases: a review.Journal of neuroinflammation · 2025Review
- Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression.European archives of psychiatry and clinical neuroscience · 2025Review
- P2X7 receptor: a potential target for treating comorbid anxiety and depression.Purinergic signalling · 2025Review
- Article
- Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry.Brain, behavior, and immunity · 2025Review
- Nuclear psychiatric imaging: the trend of precise diagnosis for mental disorders.European journal of nuclear medicine and molecular imaging · 2024Article
- Microglial Positron Emission Tomography Imaging In Vivo : Positron Emission Tomography Radioligands: Utility in Research and Clinical Practice.Advances in neurobiology · 2024Review
- Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options.European archives of psychiatry and clinical neuroscience · 2023Review
- Neuroinflammation: A Modifiable Pathway Linking Obesity, Alzheimer's disease, and Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2023Review
- Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2023Review
- Inflammation, stress and depression: An exploration of ketamine's therapeutic profile.Drug discovery today · 2023Review
- Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression.Translational psychiatry · 2023Review
- Translocator protein (18kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders?Molecular psychiatry · 2022Review
- Application of positron emission tomography in psychiatry-methodological developments and future directions.Translational psychiatry · 2022Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundGliosis is common among neuropsychiatric diseases, but the relationship between gliosis and response to therapeutics targeting effects of gliosis is largely unknown. Translocator protein total distribution volume (TSPO V
methodsA total of 41 subjects with treatment-resistant major depressive disorder underwent one [
resultsCumulative mean change in HDRS scores between 0 and 8 weeks of treatment was plotted against PFC and ACC TSPO V
conclusionsCelecoxib administration in the presence of gliosis labeled by TSPO V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.